Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance

Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A

(2022) Lloyd Wei Tat Tang et al.   DRUG METABOLISM AND DISPOSITION

Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib

(2021) Lloyd Wei Tat Tang et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4

(2021) Lloyd Wei Tat Tang et al.   DRUG METABOLISM AND DISPOSITION

Pemigatinib: First Approval

(2020) Sheridan M. Hoy   DRUGS

Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors

(2020) Hiroshi Sootome et al.   CANCER RESEARCH

Erdafitinib: First Global Approval

(2019) Anthony Markham   DRUGS

LC-MS/MS determination of erdafitinib in human plasma after SPE: Investigation of the method greenness

(2019) Tarek Elawady et al.   MICROCHEMICAL JOURNAL

Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure‒activity relationship, crystal structural characterization and in vivo study

(2018) Peng Wei et al.   Acta Pharmaceutica Sinica B

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

(2016) Young Kwang Chae et al.   Oncotarget

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

(2008) Ulrich M. Zanger et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Cholangiocarcinoma

(2008) Stefania Mosconi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY